FOXP3 and colitis: However, the chemokine-blocking treatment did not affect the body weight loss in DSS colitis model, indicating that other factors such as increased production of pro-inflammatory cytokines and decreased cLP Foxp3 Treg cell fraction play an important role in the disease development.